Eye Whitening via Low-Dose Alpha-2 Agonist Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Selective α-2 adrenergic receptor agonists used for eye whitening at conventional doses often cause undesirable side effects due to 'cross-over' stimulation of α-1 adrenergic receptors, leading to rebound hyperemia.
Innovation Solution
Low concentrations of selective α-2 adrenergic receptor agonists with high binding affinities for α-2 over α-1 receptors (100:1 or greater) are used to achieve eye whitening with reduced or eliminated side effects, utilizing compounds like brimonidine, apraclonidine, and clonidine at concentrations between 0.0001% to 0.05% weight by volume.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional doses of selective α-2 adrenergic receptor agonists (0.1% or higher) are used for eye whitening, then vasoconstriction and eye whitening effect is achieved, but reboundhyperemia and other undesirable side effects occur due to cross-over stimulation of α-1 adrenergic receptors
Solution Approach 1:
The patent changes the concentration parameter of the agonist from conventional doses (0.1% or higher) to low concentrations (0.001% to 0.05%), which fundamentally alters the receptor stimulation profile. At these low concentrations, the selective α-2 agonists preferentially bind to α-2 receptors without significant cross-over to α-1 receptors, thereby achieving vasoconstriction and eye whitening while eliminating reboundhyperemia and other undesirable side effects
Solution Approach 2:
The patent exploits the differential sensitivity and binding affinity characteristics of different adrenergic receptor subtypes. By selecting agonists with high α-2 selectivity (α-2/α-1 selectivity ratio of 100:1 or greater) and administering them at low concentrations, the treatment achieves localized effect on α-2 receptor populated arterioles and terminal arterioles in the eye, producing vasoconstriction without activating α-1 receptors that would cause harmful reboundhyperemia
2Reliability
If high concentrations of α-2 adrenergic receptor agonists are used to ensure sufficient binding to α-2 receptors, then eye whitening effect is enhanced, but cross-over stimulation ofα-1 receptors increases leading to more severe side effects
Solution Approach 1:
The patent fundamentally changes the concentration parameter from high (0.1% or higher) to low (0.001% to 0.05%), which shifts the receptor binding equilibrium. At low concentrations, the high-affinity α-2 receptors are preferentially occupied even by selective agonists, while α-1 receptors remain unactivated due to their lower affinity and the low agonist availability, thereby eliminating cross-over stimulation
Solution Approach 2:
The patent applies partial action by using sub-conventional doses of selective α-2 agonists. Instead of using full therapeutic doses that would saturate both α-2 and α-1 receptors, the patent uses low concentrations (0.001% to 0.05%) that are sufficient to activate α-2 receptors and produce vasoconstriction while remaining below the threshold for significant α-1 receptor activation, thus achieving the desired effect without harmful cross-over stimulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly improves cosmetic appearance by increasing eye whiteness and reducing hyperemia, measured on validated scales, with reduced adverse effects by preferentially targeting α-2 receptors and minimizing α-1 receptor activation.
Implementation Method 1
Agonists of these receptors may have an effect on an eye's appearance by causing lumen size reduction ofα-2 receptor populated arterioles and, particularly, terminal arterioles. This may result in vasoconstriction, and more particularly microvessel lumen size reduction
Data Source
AI summary
The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.